Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives. (Estradiol/MAM)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2010 by Scott and White Hospital & Clinic.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Scott and White Hospital & Clinic
ClinicalTrials.gov Identifier:
NCT01251263
First received: November 30, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted

November 30, 2010
November 30, 2010
October 2010
October 2012   (final data collection date for primary outcome measure)
Primary Outcome Measure [ Time Frame: 32 weeks ] [ Designated as safety issue: No ]
Comparing baseline menstrually associated migraines(MAMs) to headache occurance and severity after the implementation of continuous OC therapy.
Same as current
No Changes Posted
Secondary Outcome Measure [ Time Frame: 32 weeks ] [ Designated as safety issue: No ]
Compare effect of estradiol versus placebo on MAMs severity and duration.
Same as current
Not Provided
Not Provided
 
Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.
Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.

This study will examine the combined effects of a continuous oral contraceptive (OC) regimen with supplemental estradiol therapy on headache severity and occurrence in subjects with documented Menstrually Associated Migraines (MAMs). The subjects enrolling in the study will have cyclic menses either due to spontaneous ovulation or use of cyclic hormonal contraception (pill, patch, or ring). Enrolled subjects will start a continuous OC regimen following two baseline menstrual cycles. If breakthrough bleeding/spotting (BTB/BTS) occurs, the subject will institute a 4-day hormone-free interval (HFI). In an attempt to prevent/lessen the severity of headache during the HFI, subjects will be randomized to oral estradiol or placebo during this period. If no BTB/BTS occurs after 80 days of continuous pills, the subject will institute a 4-day HFI during which they will be randomized into estradiol or placebo groups.

The purpose of this research study is to examine the effects of continuous oral contraceptive pills and oral estradiol on headaches that occur around the time of your period. Many woman take continuous oral contraceptive pills (OC) and when OCs are stopped they may get headaches. This study will examine if taking estradiol around the time of the period will affect the headache, and how it will be affected.

This study is a prospective trial. A subject's participation will last approximately 32 weeks.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Menstrual Migraines
  • Menstrual Bleeding
  • Menstrual Spotting
  • Drug: Estradiol or Placebo
    Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
  • Drug: Estradiol or Placebo
    Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
  • Group 1
    Cyclic OC users prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
    Intervention: Drug: Estradiol or Placebo
  • Group 2
    Spontaneous ovulation group prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
    Intervention: Drug: Estradiol or Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
October 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women may be on birth control pill (OC), patch or vaginal ring taken in the traditional 21/7 or 24/4 manner, which means that every month they have a period. If they are taking it continuously (without a period), you must be willing to take your birth control 21/7 for 2 months.
  • If you are not on OC's, patch or vaginal ring you must have a period every 21-40 days.
  • You must not want to get pregnant for 12 months.
  • Women who have headaches around the time of their period.

Exclusion Criteria:

  • BMI >38
  • If you smoke and are age 35 years old or greater or if you are under 35 years old and smoke over 10 cigarettes a day.
  • If you have or had an aura with your headaches. (An aura is a temporary sensation, like bright lights that come before you experience the headache)
  • Headaches are not occuring during the time of your period.
  • Blood Pressure > 140/90 or you take more than a single antihypertensive medication (excluding diuretics) and are age 40 or greater.
  • Contraindications to combination estrogen/progestin hormonal contraceptives.
  • Desire to become pregnant in the next 12 months.
  • Stroke
  • Breast Cancer
  • Blood clots in your legs, lung or anywhere else in your body.
  • Diabetes Mellitus
  • Heart Attack
  • Liver Disease
  • Systemic Lupus Erythematosus
Female
18 Years to 45 Years
Yes
Contact: Wendy M White, CCRP 254-724-8301 wewhite@swmail.sw.org
United States
 
NCT01251263
90304
No
Patricia Sulak, MD/Principal Investigator, Scott and White Hospital & Clinic
Scott and White Hospital & Clinic
Not Provided
Principal Investigator: Patricia J Sulak, MD Scott and White Healthcare
Scott and White Hospital & Clinic
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP